Quarterly ResultMay 13, 2026, 04:07 PM
Milestone Scientific Secures $2.15M Private Placement; Q1 Net Loss Narrows to $0.84M
AI Summary
Milestone Scientific reported a significant narrowing of its net loss to $0.84 million for Q1 2026, compared to $1.99 million in Q1 2025. The company also completed a private placement in April 2026, generating $2.15 million in gross proceeds to improve its liquidity. Despite these positive developments, product sales slightly decreased to $2.16 million from $2.23 million year-over-year, and the company's recurring losses continue to raise substantial doubt about its ability to continue as a going concern.
Key Highlights
- Completed private placement in April 2026, raising $2.15 million gross proceeds.
- Q1 2026 net loss narrowed to $(839,853) from $(1,994,586) in Q1 2025.
- Product sales for Q1 2026 decreased to $2,162,033 from $2,232,420 year-over-year.
- Gross profit for Q1 2026 was $1,564,024, down from $1,647,435 year-over-year.
- Cash and cash equivalents stood at $1,194,424 as of March 31, 2026.
- Working capital was approximately $2.5 million as of March 31, 2026.
- Dental segment sales were $2,054,433 and Medical segment sales were $107,600 in Q1 2026.
- Operating loss for Q1 2026 improved to $(828,083) from $(1,997,853) in Q1 2025.